METAVIA INC. Research and Development Expense
METAVIA INC. (MTVA) reported Research and Development Expense of $3.48 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:ResearchAndDevelopmentExpense · last filed 2026-08-06
- METAVIA INC. research and development expense for the quarter ending 2026-06-30 was $3.48M, a 49.91% increase year-over-year.
- METAVIA INC. research and development expense for the quarter ending 2026-03-31 was $2.10M, a 9.71% decline year-over-year.
- METAVIA INC. research and development expense for the quarter ending 2025-12-31 was $241.00K, a 94.06% decline year-over-year.
- METAVIA INC. research and development expense for the quarter ending 2025-09-30 was $1.91M, a 57.63% decline year-over-year.
- METAVIA INC. research and development expense for fiscal 2025 was $6.80M, a 68.44% decline from fiscal 2024.
- METAVIA INC. research and development expense for fiscal 2024 was $21.55M.
| Period end | Research and Development Expense 3 month | Research and Development Expense 6 month | Research and Development Expense 9 month | Research and Development Expense 12 month |
|---|---|---|---|---|
| 2026-06-30 | $3.48M 10-Q · filed 2026-08-06 | $5.58M 10-Q · filed 2026-08-06 | $5.82M derived: sum of 3 quarters · filed 2026-08-06 | $7.73M derived: sum of 4 quarters · filed 2026-08-06 |
| 2026-03-31 | $2.10M 10-Q · filed 2026-05-14 | $2.34M derived: sum of 2 quarters · filed 2026-05-14 | $4.26M derived: sum of 3 quarters · filed 2026-05-14 | $6.58M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-12-31 | $241.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-26 | $2.15M derived: sum of 2 quarters · filed 2026-03-26 | $4.47M derived: sum of 3 quarters · filed 2026-08-06 | $6.80M 10-K · filed 2026-03-26 |
| 2025-09-30 | $1.91M 10-Q · filed 2025-11-06 | $4.23M derived: sum of 2 quarters · filed 2026-08-06 | $6.56M 10-Q · filed 2025-11-06 | $10.62M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-06-30 | $2.32M 10-Q · filed 2026-08-06 | $4.65M 10-Q · filed 2026-08-06 | $8.71M derived: sum of 3 quarters · filed 2026-08-06 | $13.22M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-03-31 | $2.33M 10-Q · filed 2026-05-14 | $6.38M derived: sum of 2 quarters · filed 2026-05-14 | $10.90M derived: sum of 3 quarters · filed 2026-05-14 | $18.98M derived: sum of 4 quarters · filed 2026-05-14 |
| 2024-12-31 | $4.06M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-26 | $8.57M derived: sum of 2 quarters · filed 2026-03-26 | $16.65M derived: sum of 3 quarters · filed 2026-03-26 | $21.55M 10-K · filed 2026-03-26 |
| 2024-09-30 | $4.52M 10-Q · filed 2025-11-06 | $12.59M derived: sum of 2 quarters · filed 2025-11-06 | $17.50M 10-Q · filed 2025-11-06 | |
| 2024-06-30 | $8.07M 10-Q · filed 2025-08-07 | $12.98M 10-Q · filed 2025-08-07 | ||
| 2020-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-13 | $0.00 derived: sum of 2 quarters · filed 2020-11-13 | $186.00K 10-Q · filed 2020-11-13 | |
| 2020-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-11 | $186.00K 10-Q · filed 2020-08-11 | ||
| 2020-03-31 | $186.00K 10-Q · filed 2020-05-20 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| KALA BIO, Inc. (KALA) | United States | $0.011B | -3.33 |
| Moleculin Biotech, Inc. (MBRX) | United States | $0.011B | |
| Theriva Biologics, Inc. (TOVX) | United States | $0.011B | |
| Azitra, Inc. (AZTR) | United States | $0.010B | -0.81 |
| Dare Bioscience, Inc. (DARE) | United States | $0.011B | |
| Medicus Pharma Ltd. (MDCX) | $0.010B | ||
| KIORA PHARMACEUTICALS INC (KPRX) | United States | $0.012B | |
| Scienture Holdings, Inc. (SCNX) | United States | $0.012B | -0.38 |
| Aprea Therapeutics, Inc. (APRE) | United States | $0.010B | -0.78 |
| Phio Pharmaceuticals Corp. (PHIO) | United States | $0.012B | -0.92 |